- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with...
Principal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster TARPON SPRINGS, Fla., June...
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity...
TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage...
Patent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide exclusivity at least into...
New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is...
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into...
Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration...
Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S....
This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential...